Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NRS 271B > CAD & ACS > Flashcards

CAD & ACS Flashcards

1
Q

Define Ischemic Heart Disease

A

narrowing of 1 or more of the coronary arteries

-this impedes coronary blood flow → deprives the tissues of oxygen supply → increases the oxygen demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the leading cause of death for both men & women in the US?

A

Heart Disease

Middle aged men > women

post-menopausal women → increased incidence 2-3x

50% manifest as chronic stable angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is under the umbrella of Ischemic Heart Disease

A
  • IHD:
    • Chronic Stable Angina
    • Acute Coronary Syndromes (ACS)
      • Unstable angina
      • Non-STEMI
      • STEMI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cardiac Conditions that are associated with Angina

A
  • Most common = atherosclerotic plaques
  • Vasospasm
    • less common → no atherosclerotic disease = Prinzmetal’s angina (beta-blockers worsen this)
  • Aortic Dissection
  • Aortic Stenosis
  • Pericarditis
  • Severe Uncontrolled HTN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Non-Cardiac Conditions Associated with Angina

A
  • anxiety
  • anemia
  • carbon monoxide poisoning
  • PUD, GERD
  • PE, pneumothorax, pulmonary HTN, thryotoxicosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Symptoms of Chronic Stable Angina

A
  • predictable
  • associated with exercise or emotional stress
  • last a short amount of time (≤ 5 min)
  • disappears with rest or use of nitro
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Symptoms of Unstable Angina

A
  • occurs even at rest
  • change in usual pattern of angina
  • unexpected
  • more severe and lasts longer than stable angina (~30min)
  • may not disappear with rest or use of angina medication
  • might signal a heart attack
  • no biomarkers (i.e. troponin is not elevated)
  • Abnormal EKG but no ST elevation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Types of Troponin

A
  • Troponin-T: 0-0.2ng/ml
    • binds to Tropomyosin
    • onset in 3-4 hours ***USED MOST OFTEN**
    • return to normal after 10-14 days
  • Troponin-I: 0-0.1ng/mL
    • Inhibits actomyosin ATPase
    • levels return to normal after 4-7 days
  • Troponin-C
    • binds to calcium to initiate contraction
    • can’t differentiate between cardiac and smooth muscle troponin-C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Types of STEMIs

A
  • Type I:
    • caused by atherothrombotic coronary artery
  • Type II:
    • mismatch of O2 supply/demand
  • Type III:
    • MI with unexpected death before drawing biomarkers
  • Type IV:
    • 4a: associated with PCI complications from procedure
    • 4b: PCI related due to stent/scaffold thrombosis
  • Type V:
    • MI associated with CABG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Primary Prevention vs Secondary Prevention

A
  • Primary Prevention:
    • before the person has the disease
  • Secondary Prevention:
    • managing the disease, preventing an event from happening AGAIN
  • BAAAS:
    • Beta-blocker
    • Anti-platelet therapy
    • ACE-I or ARB
    • Statin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

General Meds/Factors to prevent ACS and death

A
  • Control modifiable risks
    • dyslipidemia
    • HTN
    • DM
  • antiplatelet agents
  • ace-i/ARBs
  • Statins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Meds to Prevent Recurrent Ischemic Symptoms

A
  • Beta-blockers
  • CCB
  • -long-acting nitrates
  • Ranolazine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Meds to Relieve acute symptoms

A

Short Acting Nitrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Antiplatelet Classes

A

ASA and P2Y12 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ASA

A

aspirin (NSAID)

inhibits cyclooxygenase (COX enzyme) → reduces thromboxane synthesis → inhibits the activation of platelets

  • Not for adults <50 or >70
  • 81-162 mg Qday
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

P2Y12 Inhibitors

A

inhibit platelet activation and aggregation!!

  • Clopidogrel
    • prodrug (activated by 2C19) + irreversible inhibition
    • DDI with PPI (espec omeprazole)
    • Qday
  • Prasugrel
    • highest Potency
    • prodrug (unaffected by 2c19) + irreversible inhibition
    • Qday
  • Ticagrelor
    • not a prodrug
    • REVERSIBLE inhibition
    • dosing BID not Qday (so less popular)
  • SEs:
    • cough, HTN, dizziness, HA, bleeding, edema, bradycardia, dyspnea
17
Q

Nitrates MOA, DDI & SEs

A
  • MOA:
    • nitrates → nitric oxide → activates guanylate cyclase in smooth muscle → increased cGMP → release of Ca2+ from muscle cells → smooth muscle relaxation
    • primarily cause VENODILATION which reduces preload
      • but higher doses can cause arterial dilation which reduces afterload and BP
        • dilating the coronary arteries = increase oxygen supply
  • DDI: CONTRAINDICATED:
    • PDE5 inhibitors → ***severe hypotension, syncope or MI****
      • sildenafil/tadalafil
    • lidocaine → increased risk of methemoglobinemia
    • dihydroergotamine (DHE = migraine med) → decrease nitrate efficacy, increase DHE level → vasoconstriction → angina
    • EtoH → severe hypotension
  • SEs:
    • Severe hypotension
    • methemoglobinemia
      • (heme can no longer carry o2 because it has be oxidized by NO)
    • HA
    • dizziness
    • Can develop tachyphylaxis so must allow up to 14 hours of nitro free intervals Qday
18
Q

Short Acting and Long Acting Nitrates

A
  • Short-Acting Nitrates:
    • Topical:
      • nitro-bid – 2% ointment
        • need 10-12h nitrate free interval Qday
      • nitro-dur – transdermal
    • Sublingual spray:
      • nitrolingual → 1-2 sprays q5min PRN
      • Nitromist
    • Sublingual Tab:
      • nitrostat = 0.4mg SL q5min prn
  • Long Acting:
    • isosorbide mononitrate
      • dosing 1-2x/day
    • isosorbide dinitrate
      • dosing 1-3x/day
19
Q

Use of Beta-Blockers in CAD & ACS and what to avoid

A
  • Why:
    • reduce the HR → decrease myocardial oxygen demand
    • slow HR → prolong diastole → increased coronary blood flow
    • stabilize the membrane to prevent arrhythmias
    • decrease risk of reinfarction → improves survival
      • metoprolol, propranolol, carvedilol
  • Avoid:
    • the ISA + Agents (carteolol, acebutolol) because they have intrinsic sympathomimetic activity → produces a lesser reduction of oxygen demand
    • non-selective agents for asthmatic patients
    • avoid beta-blockers in treating prinzmetal angina → can WORSEN SXS
20
Q

CCB and preventing recurrent ischemic symptoms: MOA, Efficacy, & ContraIndications

A
  • MOA:
    • decrease wall tension (afterload)
    • decrease contractility → decreased myocardial demand for oxygen
    • non-dihydropyridine slow SA & AV node conduction → further decreases the oxygen demand
      • more effect as antianginal than dihydropyridine
    • dilate coronary arteries (all CCBs) → increase oxygen supply and relieve spasm
  • Efficacy:
    • same as beta blockers
    • good alternative if BB is contraindicated
    • Dihydropyridines + CCB = relieve sx better than either one alone
      • CI: do not give non-dihydropyridine + BB → SEVERE bradycardia
  • Contraindication for IHD:
    • pre-existing conduction disease without pacemaker (non-dihydropyridines)
    • concurrent use with negative inotropic agent (beta blockers)
    • short acting dihydropyridine (ie nifedipine, nicardipine)
      • high risk for hypotension
21
Q

CCB and preventing recurrent ischemic symptoms: MOA, Efficacy, & ContraIndications

A
  • MOA:
    • decrease wall tension (afterload)
    • decrease contractility → decreased myocardial demand for oxygen
    • non-dihydropyridine slow SA & AV node conduction → further decreases the oxygen demand
      • more effect as antianginal than dihydropyridine
    • dilate coronary arteries (all CCBs) → increase oxygen supply and relieve spasm
  • Efficacy:
    • same as beta blockers
    • good alternative if BB is contraindicated
    • Dihydropyridines + BB = relieve sx better than either one alone
      • CI: do not give non-dihydropyridine + BB → SEVERE bradycardia
  • Contraindication for IHD:
    • pre-existing conduction disease without pacemaker (non-dihydropyridines)
    • concurrent use with negative inotropic agent (beta blockers)
    • short acting dihydropyridine (ie nifedipine, nicardipine)
      • high risk for hypotension
22
Q

Non-dihydropyridines

A

Diltiazem & Verapamil

  • slow SA & AV node conduction → further decrease oxygen demand
  • best for antianginal use
    • better than dihydropyridines
  • decrease contractility → decreased oxygen demand
  • dilate the coronary arteries
  • good alternative if beta blockers are contraindicated
  • contraindications:
      • beta blockers → risk of SEVERE bradycardia
    • preexisting conduction disease without a pacemaker
      • short acting dihydropyridines (ie nifedipine, nicardipine)
        • high risk of Hypotension
23
Q

Ranolazine (Ranexa)

A

Approved as first line for CHRONIC STABLE ANGINA but normally reserved for refractory angina

  • Minimal effects on HR & BP
  • MOA:
    • inhibits sodium channel opening during phase 0 → prevents influx of sodium into the ICF
  • SEs:
    • QT prolongation, syncope, bradycardia
    • hypotension, tinnitus, blurred vision, vertigo
  • Contraindications:
    • liver cirrhosis
    • tx with CYP3A4 inhibitors (ketoconazole, clarithromycin, nelfinavir)
    • tx with CYP 3a4 inducers
24
Q

Summary for Stable IHD

25
Q

Treatment Algorithm for Stable Angina

26
Q

Tx of Prinzmetal Angina

A

AVOID BETA-BLOCKERS

  • For Sx relief: Nitroglycerin IR
  • if HTN = CCB effective as monotherapy +/- Long acting nitrates
    • if hypotension → LA nitrates
27
Q

Unfractionated Heparin (UFH): MOA, indications, & contraindications

A

longer sugar chain so inhibits Factor Xa + Thrombin (IIa)

  • Indications:
    • STEMI: pts undergoing PCI and pts txed with fibrinolytics
    • NSTEMI: in combo with antiplatelet therapy for conservative or invasive approach PCI
  • Contraindications:
    • active bleeding, hx of heparin-induced thrombocytopenia, severe bleeding risk, recent stroke
28
Q

Low-Molecular Weight Heparin: MOA, indications, contraindications

A

Enoxaparin**

Shorter sugar chain so only inhibits factor Xa NOT thrombin (IIa)

  • indications:
    • STEMI:in pts receiving fibrinolytics
    • NSTEMI: in combo with aspirin for conservative or invasive approach
  • Contraindications:
    • active bleeding
    • hx of heparin-induced thrombocytopenia, severe bleeding risk
    • recent stroke
    • if CrCl < 15mL/min
    • avoid if CABG surgery planned
29
Q

Bivalirudin (Angiomax)

A

Direct thrombin inhibitor → binds 2 of 3 sties on Thrombin

used when pt has heparin-induced thrombocytopenia

  • indications:
    • NSTEMI: for invasive strategy
    • PCI in STEMI
  • Contraindications:
    • active bleeding, severe bleeding risk
30
Q

Initial Tx in STEMI & NSTEMI

A

oxygen (if O2 sat <90%), SL NTG, aspirin, morphine sulfate, IV NTG

31
Q

After initial tx: STEMI ≤ 12 hours

A
  • Reperfusion Therapy:
    • Option 1:
      • higher-dose statin before primary PCI
        • then clopidogrel, prasugrel or ticagrelor (P2Y12 inhibitors → inhibit activation and aggregation of platelets
        • then Bivalirudin (thrombin inhibitor) alone or UFH + GP IIb/IIIa receptor blocker
        • then Beta-blocker, ACE-i/ARB, eplerenone (spironolactone)
    • Option 2:
      • Fibrinolysis
      • clopidogrel, statin
      • then IV UFH or IV & SC enoxaparin
      • then Beta-blocker, ACE-i/ARB, eplerenone (spironolactone)
32
Q

After initial Tx: STEMI ≥ 12 hours

A

Secondary PCI or CABG or fibrinolysis then BAAAS (beta-blocker, ACE-i/ARB, aspirin, eplerenone (spironolactone)

  • for secondary PCI during hospitalization, admin bivalirudin alone or UFH or enoxaparin with optional GP IIb/IIIa inhibitor at time of PCI
33
Q

NSTEMI tx Chart = early conservative therapy or Early invasive strategy

34
Q

Glycoprotein IIb/IIIa receptor inhibitors

A

MOA: prevent aggregation

  • abciximab
  • eptifibatide
  • tirofiban
  • Contraindications:
    • active bleeding, thrombocytopenia, prior stroke, renal dialysis (eptifibatide)
35
Q

PCI

A

also called percutaneous coronary intervention, is a procedure that uses a catheter (thin, flexible tube) and small balloon threaded through a blood vessel in the groin or arm and guided to heart to open a blocked or narrowed coronary artery

36
Q

CABG

A

Surgery in which a healthy blood vessel taken from another part of the body is used to make a new path for blood around a blocked artery leading to the heart. This restores the flow of oxygen and nutrients to the heart. Also called aortocoronary bypass and coronary artery bypass grafting

NRS 271B (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions